Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 9, 2009, Pages 600-606

  Earl, Marc ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; Adverse events; Asparaginase

Indexed keywords

ADRENALIN; AMMONIA; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTITHROMBIN; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; ASPARTIC ACID; GLUCOCORTICOID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OCTREOTIDE; PROTEINASE INHIBITOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BRONCHOSPASM; CONTINUOUS INFUSION; DIET THERAPY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENZYME SYNTHESIS; EXERCISE; FEVER; FLUSHING; GROWTH INHIBITION; HUMAN; HYPERGLYCEMIA; HYPOFIBRINOGENEMIA; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE ULCER; LEUKEMIA CELL; LIVER DISEASE; LYMPHOBLAST; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PROTEIN C DEFICIENCY; PROTEIN DEPLETION; PROTEIN S DEFICIENCY; PROTEIN SYNTHESIS INHIBITION; RASH; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS; URTICARIA;

ADULT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; BLOOD COAGULATION DISORDERS; CHILD; DRUG HYPERSENSITIVITY; HUMANS; INCIDENCE; LIVER; PANCREATITIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 70349664304     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Asselin BL, Ryan D, Frantz CN, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989;49:4363-4368.
2. Asselin BL, Lorenson MY, Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 1991;51:6568-6573.
3. Capizzi RL, Bertino JR, Handschumacher RE. L-asparaginase. Annu Rev Med. 1970;21:433-444.
4. Kafkewitz D, Bendich A. Enzyme-induced asparagine and glutamine depletion and immune system function. Am J Clin Nutr. 1983;37:10251-030.
5. Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 1970;25:306-320.
6. Jones B, Holland JF, Glidewell O, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol. 1977;3:387-400.
7. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
8. Zakarija A. Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost. 2007;33:355-364.
9. Cairo MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 1982;4:335-339.
10. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. National Cancer Institute. March 31, 2003 (http://ctep.cancer.gov). August 9, 2006. Accessed February 20, 2009.
11. Mitchell LG, Halton JM, Vegh PA, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1994;16:120-126.
12. Miniero R, Pastore G, Saracco P, et al. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Am J Pediatr Hematol Oncol. 1986;8:116-120.
13. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia: part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res. 2003;111:199-212.
14. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia: part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res. 2003;111:321-327.
15. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli/prednisone administration. Thromb Res. 2001;103:165-172.
16. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007;138:430-435.
17. Mitchell LG, Sutor AN, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21:390-401.
18. Revel-Vilk S. Central venous line-related thrombosis in children. Acta Haematol. 2006;115:201-206.
19. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion. 2006:74:28-32.
20. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67:101-154.
21. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol. 1997;26(suppl 2):43-53.
22. Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis. 2003;23:295-299.
23. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986-1994.
24. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 1976;37:220-228.
25. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. Coli asparaginase in man. Cancer. 1970;25:253-278.
26. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007; 109:2744-2750.
27. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/ Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 8501. J Clin Oncol. 1994;12:740-747.
28. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896-904.
29. Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100:984-89.
30. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res. 2003;111:125-131.
31. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77:331-335.
32. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216-2222.
33. Mitchell LG, Andrew M, Hanna K, Abshire T, Anderson R, Cherrick I. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer. 2003;97:508-516.
34. Garrington T, Bensard D, Ingram JD, Silliman CC. Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis. Med Pediatr Oncol. 1998;30:106-109.
35. Suzuki M, Takata O, Sakaguchi S, Fujimura J, Saito M, Shimizu T. Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparaginase-induced pancreatitis. Exp Hematol. 2008;36:253-254.
36. Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia. J Med. 1994;25:219-229.
37. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002;16:225-243.
38. Advani A, Earl M, Douer D, Rytting M, Bleyer A. Toxicities of intravenous (IV) pegasparaginase (ONCASPAR) in adults with acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts). 2007; Abstract 2811.
39. Rytting, M, Earl M, Douer D, Muriera B, Advani A, Bleyer A. MD5 toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase. Blood (ASH Annual Meeting Abstracts). 2008;112:1924.
40. Gugliotta L, Massucconi MG, Leone G, et al. Incidence of thrombotic complications in adult patients with lymphoblastic leukemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol. 1992;49:63-66.
41. Melillo L, Grandone E, Colazzo D, Cappucci F, Valvano MR, Cascavilla N. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol. 2007;117:215-220.
42. Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93:1488-1494.
43. Sutor AH, Mall V, Thomas KB. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Padiatr. 1999;211:201-204.
44. Abuchowski A, Kazo GM, Verhoest CR Jr, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycolasparaginase conjugates. Cancer Biochem Biophys. 1984;7:175-186.
45. Wiernikowski JT, Athale UH. Thromboembolic complications in children with cancer. Thromb Res. 2006;118:137-152.
46. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
47. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with hig-hrisk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548-2555.
48. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12:991-998.
49. Dhall G, Robison NJ, Rubin JI, et al. Incidence of adverse reactions to post-induction asparaginase (ASP) therapy in children and adolescents with high-risk acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group Study CCG-1961. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:110021.
50. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organization for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99:2734-2739.
51. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61:208-221.
52. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia ASNase in children with leukemia and lymphoma. Cancer. 1982;49:1378-1383.
53. Wiernikowski JT, Athale UH. Thromboembolic complications in children with cancer. Thromb Res. 2006;118:137-152.
54. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children. Chest. 2004;126:645S-687S.
55. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007;138:430-435.
56. Banks PA, Freeman ML, and the Practice Parameters Committee of the American College of Gastroenterology. Practice Guidelines in Acute Pancreatitis. Am J Gastroenterol. 2006;101:2379-2400.
57. Top PC, Tissing WJ, Kuiper JW, Pieters R, van Eijck CH. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer. 2005;44:95-97.
58. Morimoto A, Imamura T, Ishii R, et al. Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer. 2008;113:1362-1369.
59. Paran H, Neufeld D, Mayo A, et al. Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg. 1995;181:121-124.
60. Tauber MT, Harris AG, Rochiccioli P. Clinical use of the long acting somatostatin analogue octreotide in pediatrics. Eur J Pediatr. 1994;153:304-310.
61. Wu S, Chen A, Peng C, et al. Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:824-825.
62. Suzuki M. Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparaginase-induced pancreatitis. Exper Hematol. 2008;36:253-254.
63. Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2007;49:634-639.